JP5684580B2 - 急性冠症候群後の予後診断におけるプロカルシトニン(pct)の使用 - Google Patents
急性冠症候群後の予後診断におけるプロカルシトニン(pct)の使用 Download PDFInfo
- Publication number
- JP5684580B2 JP5684580B2 JP2010550105A JP2010550105A JP5684580B2 JP 5684580 B2 JP5684580 B2 JP 5684580B2 JP 2010550105 A JP2010550105 A JP 2010550105A JP 2010550105 A JP2010550105 A JP 2010550105A JP 5684580 B2 JP5684580 B2 JP 5684580B2
- Authority
- JP
- Japan
- Prior art keywords
- procalcitonin
- concentration
- fragment
- pct
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108010048233 Procalcitonin Proteins 0.000 title claims description 105
- CWCXERYKLSEGEZ-KDKHKZEGSA-N procalcitonin Chemical compound C([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(O)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@@H](N)CSSC1)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 CWCXERYKLSEGEZ-KDKHKZEGSA-N 0.000 title claims description 105
- 208000004476 Acute Coronary Syndrome Diseases 0.000 title claims description 34
- 238000004393 prognosis Methods 0.000 title claims description 7
- 239000012634 fragment Substances 0.000 claims description 30
- 206010019280 Heart failures Diseases 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 22
- 230000002411 adverse Effects 0.000 claims description 17
- 230000034994 death Effects 0.000 claims description 17
- 231100000517 death Toxicity 0.000 claims description 17
- 102100036836 Natriuretic peptides B Human genes 0.000 claims description 12
- 101710187802 Natriuretic peptides B Proteins 0.000 claims description 12
- 238000003556 assay Methods 0.000 claims description 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 11
- 150000001413 amino acids Chemical class 0.000 claims description 8
- 208000010125 myocardial infarction Diseases 0.000 claims description 8
- 210000004369 blood Anatomy 0.000 claims description 6
- 239000008280 blood Substances 0.000 claims description 6
- 239000003550 marker Substances 0.000 claims description 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 6
- 102400000667 Brain natriuretic peptide 32 Human genes 0.000 claims description 5
- 238000001514 detection method Methods 0.000 claims description 5
- 210000002966 serum Anatomy 0.000 claims description 5
- 229960004015 calcitonin Drugs 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 4
- 102000055006 Calcitonin Human genes 0.000 claims description 3
- 108060001064 Calcitonin Proteins 0.000 claims description 3
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims description 3
- 239000005556 hormone Substances 0.000 claims description 3
- 229940088597 hormone Drugs 0.000 claims description 3
- 239000002243 precursor Substances 0.000 claims description 3
- 230000035945 sensitivity Effects 0.000 claims description 3
- 101800004616 Adrenomedullin Proteins 0.000 claims description 2
- 102000012192 Cystatin C Human genes 0.000 claims description 2
- 108010061642 Cystatin C Proteins 0.000 claims description 2
- 108050009340 Endothelin Proteins 0.000 claims description 2
- 102000002045 Endothelin Human genes 0.000 claims description 2
- 108010041834 Growth Differentiation Factor 15 Proteins 0.000 claims description 2
- 102000000597 Growth Differentiation Factor 15 Human genes 0.000 claims description 2
- 101000852968 Homo sapiens Interleukin-1 receptor-like 1 Proteins 0.000 claims description 2
- 101000585365 Homo sapiens Sulfotransferase 2A1 Proteins 0.000 claims description 2
- 102400000569 Myeloperoxidase Human genes 0.000 claims description 2
- 108090000235 Myeloperoxidases Proteins 0.000 claims description 2
- 102100029867 Sulfotransferase 2A1 Human genes 0.000 claims description 2
- BMQYVXCPAOLZOK-UHFFFAOYSA-N Trihydroxypropylpterisin Natural products OCC(O)C(O)C1=CN=C2NC(N)=NC(=O)C2=N1 BMQYVXCPAOLZOK-UHFFFAOYSA-N 0.000 claims description 2
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 claims description 2
- 108010004977 Vasopressins Proteins 0.000 claims description 2
- 102000002852 Vasopressins Human genes 0.000 claims description 2
- ULCUCJFASIJEOE-NPECTJMMSA-N adrenomedullin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(=O)N[C@@H]1C(N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CSSC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)[C@@H](C)O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 ULCUCJFASIJEOE-NPECTJMMSA-N 0.000 claims description 2
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 claims description 2
- 239000002934 diuretic Substances 0.000 claims description 2
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 claims description 2
- 230000001452 natriuretic effect Effects 0.000 claims description 2
- BMQYVXCPAOLZOK-XINAWCOVSA-N neopterin Chemical compound OC[C@@H](O)[C@@H](O)C1=CN=C2NC(N)=NC(=O)C2=N1 BMQYVXCPAOLZOK-XINAWCOVSA-N 0.000 claims description 2
- 229960003726 vasopressin Drugs 0.000 claims description 2
- 102000004379 Adrenomedullin Human genes 0.000 claims 1
- 102400001263 NT-proBNP Human genes 0.000 description 26
- 108010008064 pro-brain natriuretic peptide (1-76) Proteins 0.000 description 26
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 description 25
- 208000029078 coronary artery disease Diseases 0.000 description 11
- 230000004083 survival effect Effects 0.000 description 10
- 208000006117 ST-elevation myocardial infarction Diseases 0.000 description 8
- 206010000891 acute myocardial infarction Diseases 0.000 description 8
- 206010040047 Sepsis Diseases 0.000 description 7
- 206010002388 Angina unstable Diseases 0.000 description 6
- 208000000770 Non-ST Elevated Myocardial Infarction Diseases 0.000 description 6
- 208000007814 Unstable Angina Diseases 0.000 description 6
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 6
- 230000004087 circulation Effects 0.000 description 5
- 210000004351 coronary vessel Anatomy 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 206010008479 Chest Pain Diseases 0.000 description 4
- 108060006698 EGF receptor Proteins 0.000 description 4
- 208000007718 Stable Angina Diseases 0.000 description 4
- 238000001325 log-rank test Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 230000002861 ventricular Effects 0.000 description 4
- 206010002383 Angina Pectoris Diseases 0.000 description 3
- 101800001288 Atrial natriuretic factor Proteins 0.000 description 3
- 102400001282 Atrial natriuretic peptide Human genes 0.000 description 3
- 101800001890 Atrial natriuretic peptide Proteins 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 102000011779 Nitric Oxide Synthase Type II Human genes 0.000 description 3
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 3
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 238000007473 univariate analysis Methods 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 102100032752 C-reactive protein Human genes 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 102000004903 Troponin Human genes 0.000 description 2
- 108090001027 Troponin Proteins 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000000700 radioactive tracer Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- VXGOQVMIGNMUGC-UHFFFAOYSA-N 1-methylacridine Chemical compound C1=CC=C2C=C3C(C)=CC=CC3=NC2=C1 VXGOQVMIGNMUGC-UHFFFAOYSA-N 0.000 description 1
- XMTQQYYKAHVGBJ-UHFFFAOYSA-N 3-(3,4-DICHLOROPHENYL)-1,1-DIMETHYLUREA Chemical compound CN(C)C(=O)NC1=CC=C(Cl)C(Cl)=C1 XMTQQYYKAHVGBJ-UHFFFAOYSA-N 0.000 description 1
- 102400001318 Adrenomedullin Human genes 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 200000000007 Arterial disease Diseases 0.000 description 1
- 206010003225 Arteriospasm coronary Diseases 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 108010074051 C-Reactive Protein Proteins 0.000 description 1
- 102000012421 C-Type Natriuretic Peptide Human genes 0.000 description 1
- 101800000060 C-type natriuretic peptide Proteins 0.000 description 1
- 102000004414 Calcitonin Gene-Related Peptide Human genes 0.000 description 1
- 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000003890 Coronary Vasospasm Diseases 0.000 description 1
- 206010052895 Coronary artery insufficiency Diseases 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 208000002476 Falciparum Malaria Diseases 0.000 description 1
- 101500026734 Homo sapiens NT-proBNP Proteins 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 238000010824 Kaplan-Meier survival analysis Methods 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 206010027202 Meningitis bacterial Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 201000011336 Plasmodium falciparum malaria Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 206010071436 Systolic dysfunction Diseases 0.000 description 1
- 102100036859 Troponin I, cardiac muscle Human genes 0.000 description 1
- 101710128251 Troponin I, cardiac muscle Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- -1 age Proteins 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 208000028922 artery disease Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 201000009904 bacterial meningitis Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 108091006374 cAMP receptor proteins Proteins 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 230000008828 contractile function Effects 0.000 description 1
- 201000011634 coronary artery vasospasm Diseases 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 238000002592 echocardiography Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 208000037906 ischaemic injury Diseases 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 208000023589 ischemic disease Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 230000008383 multiple organ dysfunction Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003680 myocardial damage Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000037891 myocardial injury Diseases 0.000 description 1
- 230000008035 nerve activity Effects 0.000 description 1
- 239000000712 neurohormone Substances 0.000 description 1
- 102000008434 neuropeptide hormone activity proteins Human genes 0.000 description 1
- 108040002669 neuropeptide hormone activity proteins Proteins 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 208000021090 palsy Diseases 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- RXNXLAHQOVLMIE-UHFFFAOYSA-N phenyl 10-methylacridin-10-ium-9-carboxylate Chemical compound C12=CC=CC=C2[N+](C)=C2C=CC=CC2=C1C(=O)OC1=CC=CC=C1 RXNXLAHQOVLMIE-UHFFFAOYSA-N 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 230000012495 positive regulation of renal sodium excretion Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000036454 renin-angiotensin system Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008718 systemic inflammatory response Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000010967 transthoracic echocardiography Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
ACSの患者974名の退院前(predischarge)(3〜5日)に取得した血漿中PCTレベルは、正常範囲と比較して上昇していた(表2)。正常個体の中間PCT値は、0.0127μg/1であった(Morgenthaler NG et al.: Detection of procalcitonin (PCT) in healthy controls and patients with local infection by a sensitive ILMA. Clin Lab. 2002, 48, (5−6), 263−270)。男性患者のPCTレベルは、女性の場合と比較して低かった(表2)。急性心筋梗塞(AMI)、高血圧、糖尿病又は心不全(HF)の病歴がある患者のPCTレベルは、そのような病歴の無い患者と比較して高かった。PCTのレベルは、他の部位の梗塞のものと前壁心筋梗塞のものとが類似しており、又はNSTEMIのものとSTEMIのものとが類似していた(表2)。Killip分類が1より高い(左室収縮能の低下の発生を示す)ものにおいてPCTレベルの上昇が見られ、これは、心エコー検査により収縮機能障害の兆候が認められた患者においてPCTレベルの亢進が見出されたことにより確認された(表2)。
退院前のフェーズ(3〜5日)で取得した血漿NT−プロBNPは、無症候生存の患者と比較して、死亡又はHFにより再入院した患者において、顕著に高かった(表2)。男性と女性との間で、Killip分類が1を超える患者において、そして心不全、高血圧、心筋梗塞又は糖尿病の病歴がある患者において、NT−プロBNPレベルの顕著な差異が注目された(表2)。また、NT−プロBNPのレベルは、NSTEMI患者よりもSTEMI患者において高かったが、前部AMIの患者においてはそのようにならなかった。血漿NT−プロBNPは、年齢、eGFR、Killip分類と関連付けられた(表2)。
死亡又はHFの単変量予測因子は、表3に報告されている。PCT(0.69[95%信頼区間CI:0.65−0.73])及びNT−プロBNP(0.76 [95%CI:0.72−0.79])の受信者動作特性曲線の下部面積(AUC ROC)は、同程度であった。
PCT及びNT−プロBNPは、無症候性損の患者と比較して、死亡した患者において、顕著に高かった(表2)。Cox比例ハザードモデルは、同一の変数(PCT、NT−プロBNP、年齢及びAMIの病歴)が、死亡の独立した予測因子であることを示していた。Kaplan−Meier解析により、NT−プロBNP中間値により階層化された両方のグループにおいて、前記PCTレベルが前記中間値を下回る患者の死亡率が低いことが確認された(中間NT−プロBNPレベルを下回る患者においてはP<0.01(ログランク検定を使用)、中間NT−プロBNPレベルを上回る患者においてはP<0.001(ログランク検定を使用))。
Claims (11)
- 急性冠症候群(acute coronary syndrome)の患者の予後をインビトロで決定する方法であり:
該患者から取得した試料中のプロカルシトニン又は長さが12アミノ酸以上のその断片の濃度を決定し;
そして該プロカルシトニン又はその断片の濃度と該急性冠症候群の有害転帰への素因とを関連付けることを含み、ここで、当該関連付けの工程が、前記プロカルシトニン又はその断片の濃度と0.045(+/−0.010)μg/Lである閾値とを比較して、ここで該プロカルシトニン又はその断片の濃度が該閾値を越えている場合に、前記患者が有害転帰の素因を有すると決定することを含む、決定方法。 - 前記有害転帰が、死亡、心不全及び心筋梗塞からなる群から選択される、請求項1に記載の方法。
- 前記試料が、血液試料、血清試料、及び血漿試料を含む群から選択される、請求項1又は2のいずれか1項に記載の方法。
- 更に、前記プロカルシトニン又はその断片の濃度と、1つ以上の追加的な予後マーカーの濃度とを関連付けて、ここで該プロカルシトニン又はその断片の濃度と該追加的な予後マーカーの濃度との組合せが、該プロカルシトニン若しくはその断片の濃度の、又は前記関連するマーカーの濃度の、前記有害転帰における診断価値を増大させることを含む、請求項1〜3のいずれか1項に記載の方法。
- 前記予後マーカーの1つが、前記患者から取得したプレ−プロBNP又はその断片である、請求項4に記載の方法。
- 前記プレ−プロBNPの断片が、NTプロ−BNP又はBNPである、請求項5に記載の方法。
- 更に、前記患者から取得した試料中の1つ以上の追加的な予後マーカーの濃度を決定し、そして前記プロカルシトニン又はその断片の濃度及び該1つ以上の追加的な予後マーカーの濃度の両方と前記有害転帰への素因を関連付け、ここで該プロカルシトニン又はその断片の濃度と該1つ以上の追加的な予後マーカーの濃度との組合せが、該プロカルシトニン若しくはその断片の濃度の該有害転帰における診断価値を増大させることを含む、請求項4〜6のいずれか1項に記載の方法。
- 前記追加的な予後マーカーが、トロポニン、ミエロペルオキシダーゼ、CRP、ネオプテリン、GDF−15、ST2、シスタチンC、並びに成熟ペプチド、前駆体、プロ−ホルモン及び関連するプロホルモン断片の形態の以下のペプチド:ナトリウム利尿ペプチド、アドレノメドゥリン(adrenomedullin)、エンドセリン、バソプレシンからなる群から選択される、請求項4〜7のいずれか1項に記載の方法。
- 前記プロカルシトニン又はその断片の濃度と前記1つ以上の追加的な予後マーカーの濃度との関連付けが、数学的アルゴリズムを用いて行われる、請求項4〜8のいずれか1項に記載の方法。
- 患者中の急性冠症候群の有害転帰への素因を決定するための請求項1〜9のいずれか1項に記載の方法における、検出感度の下限が<0.045(+/−0.010)μg/Lであり、プロカルシトニンの異なる部分に対する2つの抗体を含むサンドイッチアッセイである、プロカルシトニンを検出するアッセイの使用。
- 1つの抗体がプロカルシトニンのカルシトニン部分に対し、そしてもう1つの抗体がプロカルシトニンのカタカルシンに対するモノクローナル抗体である、請求項10に記載のプロカルシトニンを検出するアッセイの使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08152651.9 | 2008-03-12 | ||
EP08152651A EP2101178A1 (en) | 2008-03-12 | 2008-03-12 | Use of Procalcitonin (PCT) in prognosis following acute coronary syndromes |
PCT/EP2009/051036 WO2009112307A1 (en) | 2008-03-12 | 2009-01-29 | Use of procalcitonin (pct) in prognosis following acute coronary syndromes |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2011514971A JP2011514971A (ja) | 2011-05-12 |
JP5684580B2 true JP5684580B2 (ja) | 2015-03-11 |
Family
ID=39791267
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010550105A Active JP5684580B2 (ja) | 2008-03-12 | 2009-01-29 | 急性冠症候群後の予後診断におけるプロカルシトニン(pct)の使用 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20110117589A1 (ja) |
EP (2) | EP2101178A1 (ja) |
JP (1) | JP5684580B2 (ja) |
CN (1) | CN102007415B (ja) |
DK (1) | DK2255202T3 (ja) |
ES (1) | ES2641912T3 (ja) |
HK (1) | HK1153539A1 (ja) |
WO (1) | WO2009112307A1 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2320237B1 (en) * | 2009-10-13 | 2016-08-03 | B.R.A.H.M.S GmbH | Procalcitonin for the diagnosis of bacterial infections and guidance of antibiotic treatment in patients with acute stroke or transient ischemic attack |
EP2742348A4 (en) * | 2011-08-12 | 2015-07-22 | Alfred Health | METHOD FOR THE DIAGNOSIS, FORECAST OR TREATMENT OF ACUTE CORONARY SYNDROME (ACS) BY MEASUREMENT OF THE PLASMA CONCENTRATION OF THE MACROPHAGE MIGRATION INHIBITION FACTOR (MIF) |
CN104303061B (zh) * | 2012-04-12 | 2017-05-31 | B.R.A.H.M.S有限公司 | 患有疑似慢性心力衰竭的患者中不良事件的预后 |
US11143659B2 (en) | 2015-01-27 | 2021-10-12 | Arterez, Inc. | Biomarkers of vascular disease |
EP3502706A1 (en) * | 2017-12-20 | 2019-06-26 | B.R.A.H.M.S GmbH | Workflow for risk assessment and patient management using procalcitonin and midregional-proadrenomedullin |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6147688A (en) | 1993-06-28 | 2000-11-14 | Athena Design Systems, Inc. | Method and apparatus for defining and selectively repeating unit image cells |
US5795725A (en) | 1995-04-18 | 1998-08-18 | Biosite Diagnostics Incorporated | Methods for the assay of troponin I and T and selection of antibodies for use in immunoassays |
US6156521A (en) | 1997-12-19 | 2000-12-05 | Biosite Diagnostics, Inc. | Methods for the recovery and measurement of troponin complexes |
US5947124A (en) | 1997-03-11 | 1999-09-07 | Biosite Diagnostics Incorporated | Diagnostic for determining the time of a heart attack |
US7632647B2 (en) * | 2001-04-13 | 2009-12-15 | Biosite Incorporated | Use of B-type natriuretic peptide as a prognostic indicator in acute coronary syndromes |
US20040253637A1 (en) * | 2001-04-13 | 2004-12-16 | Biosite Incorporated | Markers for differential diagnosis and methods of use thereof |
CA2522709A1 (en) * | 2003-04-17 | 2004-11-04 | Ciphergen Biosystems, Inc. | Polypeptides related to natriuretic peptides and methods of their identification and use |
-
2008
- 2008-03-12 EP EP08152651A patent/EP2101178A1/en not_active Withdrawn
-
2009
- 2009-01-29 US US12/921,885 patent/US20110117589A1/en not_active Abandoned
- 2009-01-29 CN CN200980108835.6A patent/CN102007415B/zh active Active
- 2009-01-29 DK DK09719129.0T patent/DK2255202T3/en active
- 2009-01-29 EP EP09719129.0A patent/EP2255202B1/en active Active
- 2009-01-29 ES ES09719129.0T patent/ES2641912T3/es active Active
- 2009-01-29 WO PCT/EP2009/051036 patent/WO2009112307A1/en active Application Filing
- 2009-01-29 JP JP2010550105A patent/JP5684580B2/ja active Active
-
2011
- 2011-07-22 HK HK11107632.6A patent/HK1153539A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
EP2255202A1 (en) | 2010-12-01 |
WO2009112307A1 (en) | 2009-09-17 |
HK1153539A1 (en) | 2012-03-30 |
US20110117589A1 (en) | 2011-05-19 |
JP2011514971A (ja) | 2011-05-12 |
DK2255202T3 (en) | 2017-10-23 |
EP2255202B1 (en) | 2017-08-02 |
CN102007415B (zh) | 2014-12-10 |
CN102007415A (zh) | 2011-04-06 |
ES2641912T3 (es) | 2017-11-14 |
EP2101178A1 (en) | 2009-09-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Maisel et al. | Natriuretic peptides in heart failure: atrial and B-type natriuretic peptides | |
EP1983058B1 (en) | Use of B-type natriuretic peptide as a prognostic indicator in acute coronary syndromes | |
Yalta et al. | Copeptin and cardiovascular disease: a review of a novel neurohormone | |
Steadman et al. | Natriuretic peptides in common valvular heart disease | |
US9012151B2 (en) | Methods of diagnosis and risk stratification of adverse events in post myocardial infarction patients using pro-adrenomedullin | |
JP6419794B2 (ja) | 主要な心臓有害事象に罹患する危険性を予測する方法 | |
US8252544B2 (en) | Diagnosis and risk stratification of cardiac insufficiency by means of natriuretic peptides for NYHA I patients | |
US20150362511A1 (en) | Assessing susceptibility to cardiac intervention, susceptibility to therapy for heart failure, risk of mortality or further cardiovascular events, and risk of subsequent pulmonary embolism in relevant patients based on determinations of gdf-15, natriuretic peptide, cardiac troponin or combinations thereof | |
AU2002252636A1 (en) | Use of B-type natriuretic peptide as a prognostic indicator in acute coronary syndromes | |
JP5684580B2 (ja) | 急性冠症候群後の予後診断におけるプロカルシトニン(pct)の使用 | |
Vanderheyden et al. | Head to head comparison of N-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in patients with/without left ventricular systolic dysfunction | |
Choudhary et al. | Heart failure biomarkers | |
JP2011528792A (ja) | 心臓病性疾患におけるマーカーとしての好アズール性顆粒 | |
Gori et al. | Role of biomarkers in patients with dyspnea. | |
Weber et al. | The diagnostic and prognostic value of brain natriuretic peptide and aminoterminal (nt)-pro brain natriuretic peptide | |
Maewal et al. | Natriuretic peptide hormone measurement in acute coronary syndromes | |
Elmas et al. | Midregional pro-atrial natriuretic peptide is a useful indicator for the detection of impaired left ventricular function in patients with coronary artery disease | |
Jarai et al. | Circulating B-type natriuretic peptides in patients with acute coronary syndromes | |
JP5362487B2 (ja) | proBNP−108の新規用途 | |
Staszewsky et al. | Total NT-proBNP, a novel biomarker in atrial fibrillation. A mechanistic analysis of the GISSI-AF trial | |
Abdel-Rhman et al. | Role of Tenascin-C as a Predictor of Left Ventricular Remodeling after streptokinase in patients with acute Myocardial Infarction | |
Sheikh et al. | Comparison between the Levels of N Terminal Pro-Brain Natriuretic Peptide and Troponin I to Predict Left Ventricular Ejection Fraction in Patients Presenting with First ST-Elevation Myocardial Infarction | |
Ma et al. | NT-probnp Variability as a Predictor of Adverse Outcomes in Patients With Cardiorenal Syndrome Type 2 | |
Israr | Processed BNP Molecular Forms As A New Generation Biomarker In Cardiovascular Disease | |
Choudhary et al. | Oxford Medicine Online |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20111021 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20120926 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121002 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130104 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130730 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131030 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140218 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140319 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140610 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140709 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20141216 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150115 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5684580 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |